Footonomics by Jakobsen & Garnry #2

Footonomics by Jakobsen & Garnry #2

Equities 5 minutes to read
Peter Garnry

Chief Investment Strategist

Summary:  Today's Footonomics is about Denmark vs Finland which are playing the first match in group B. Denmark wins on macro with a superior Misery Index - it is wonderful to be a Dane after all. On equities the match is between Novo Nordisk and Neste, which the Danish pharmaceutical company wins 2-1 on better equity fundamentals despite Neste being a high quality oil refiner. Steen's and Peter's prediction is that Denmark wins 1-0 over Finland.


Match: Denmark vs Finland

Macro: Danish Dynamite vs. Finnish Sisu

  • Denmark has clear win on the Misery Index (CPI + Unemployment + Budget deficit) with the low score of 8.3 vs. Finlands 13.7. Unemployment being the big difference.
  • Denmark is ranked 51st in GDP globally vs. Finland 57th. A draw.

  • Denmark has most losses in the European Championship at 14 (Whaaaaaat….) vs. Finlands 1st ever Championship. Congratulations. Finland win as the 1st Championship is amazing result.

  • Best football quotes: Denmark. Richard Møller Nielsen, the winning 1992 national coach: “..We must screw down the expectations. We change our tactic and play with long balls” vs. Finland. “Jari Litmanen should be made compulsory” Ron Atkinson. How can you beat..” long balls??… Denmark win.

Equities: Novo Nordisk vs Neste

  • Novo Nordisk, the world’s largest insulin maker, wins 2-1 over Neste, one of Europe’s largest oil refiners, as the Danish pharmaceutical company is cheaper on valuation (22.9 vs 25.4 on 24-month forward P/E ratio) and has a better return on equity (75.9% vs 23.3%). Neste scores a goal on a slightly higher expected growth rate (9.0% vs 8.1%). Neste is one of the highest quality companies in Europe but battling another high quality company is just a tough match.

  • Novo Nordisk has been riding the diabetes disease for decades with the Chinese looking to be the next growth leg. A recent spinoff of the company’s insulin drugs is a new weight loss drug that has just got FDA approval based on trials showing 15% weight reduction, which according to Obesity Medicine Association is a “game changer”.

  • Neste has performed outstanding over the past decade lifting operating margins from around 5% to around 17% today. Recently the refiner has taking the lead on renewable diesel and jet fuel as the refiner is transitioning its business towards the green transformation.

Quarterly Outlook

01 /

  • Equity outlook: The high cost of global fragmentation for US portfolios

    Quarterly Outlook

    Equity outlook: The high cost of global fragmentation for US portfolios

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: Commodities rally despite global uncertainty

    Quarterly Outlook

    Commodity Outlook: Commodities rally despite global uncertainty

    Ole Hansen

    Head of Commodity Strategy

  • Upending the global order at blinding speed

    Quarterly Outlook

    Upending the global order at blinding speed

    John J. Hardy

    Global Head of Macro Strategy

    We are witnessing a once-in-a-lifetime shredding of the global order. As the new order takes shape, ...
  • Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Quarterly Outlook

    Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    Quarterly Outlook

    Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    John J. Hardy

    Global Head of Macro Strategy

  • Equity Outlook: The ride just got rougher

    Quarterly Outlook

    Equity Outlook: The ride just got rougher

    Charu Chanana

    Chief Investment Strategist

  • China Outlook: The choice between retaliation or de-escalation

    Quarterly Outlook

    China Outlook: The choice between retaliation or de-escalation

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: A bumpy road ahead calls for diversification

    Quarterly Outlook

    Commodity Outlook: A bumpy road ahead calls for diversification

    Ole Hansen

    Head of Commodity Strategy

  • FX outlook: Tariffs drive USD strength, until...?

    Quarterly Outlook

    FX outlook: Tariffs drive USD strength, until...?

    John J. Hardy

    Global Head of Macro Strategy

  • Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Quarterly Outlook

    Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Althea Spinozzi

    Head of Fixed Income Strategy

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Capital Markets UK Ltd. (Saxo) and the Saxo Bank Group provides execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice nor a recommendation. Access and use of this website is subject to: (i) the Terms of Use; (ii) the full Disclaimer; (iii) the Risk Warning; and (iv) any other notice or terms applying to Saxo’s news and research.

Saxo’s content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

Please refer to our full disclaimer for more details.

Saxo
40 Bank Street, 26th floor
E14 5DA
London
United Kingdom

Contact Saxo

Select region

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo is a registered Trading Name of Saxo Capital Markets UK Ltd (‘Saxo’). Saxo is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992